Skip to main content
PMC home page
Springer logoLink to Springer
. 2021 Sep 16;100(11):2877–2878. doi: 10.1007/s00277-021-04638-1

Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

Thomas Heinicke 1, Rainer Krahl 2, Christoph Kahl 3, Michael Cross 2, Sebastian Scholl 4, Hans‑Heinrich Wolf 5, Detlev Hähling 6, Ute Hegenbart 7, Norma Peter 8, Antje Schulze 9, Axel Florschütz 10, Volker Schmidt 9, Kolja Reifenrath 11, Niklas Zojer 12, Christian Junghanss 13, Herbert G Sayer 9, Georg Maschmeyer 14, Christian Späth 15, Andreas Hochhaus 4, Thomas Fischer 1, Haifa Kathrin Al‑Ali 5, Dietger Niederwieser 2,16,17,✉
PMCID: PMC9172780  PMID: 34529106

Correction to : Annals of Hematology

https://doi.org/10.1007/s00277-021–04465-4

The first name of authors were erroneously presented (correct Volker Schmidt instead of Schmidt Volker; correct Christian Späth instead of Späth Wolfgang). In Fig. 2B, the n value of de novo AML should be 389 instead of 369. In Fig. 2D, the n value of ≤ 6 months should be 271 instead of 86 and the n value of > 18 months should be 86 instead of 271.

Fig. 2.

Fig. 2

Open in a new tab

(Relapsed patients). A Overall survival (OS) of patients with AML after frst relapse according to age. B Overall survival (OS) of patients with AML after frst relapse according to de novo, secondary, and therapy-related AML. C Overall survival (OS) of patients with AML after frst relapse according to favorable, intermediate, and unfavorable cytogenetics. D Overall survival (OS) of patients with AML after frst relapse according to time interval CR1 and relapse in months

The original article has been corrected.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Articles from Annals of Hematology are provided here courtesy of Springer

RESOURCES